Mike Panos - Stryker North RD
| SYK Stock | USD 335.54 0.00 0.00% |
Executive
Mike Panos is North RD of Stryker
| Address | 1941 Stryker Way, Portage, MI, United States, 49002 |
| Phone | 269 385 2600 |
| Web | https://www.stryker.com |
Stryker Management Efficiency
The company has Return on Asset of 0.0723 % which means that on every $100 spent on assets, it made $0.0723 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1864 %, implying that it generated $0.1864 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Stryker's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Return On Tangible Assets will most likely fall to 0.10. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kelley Nicholas | Neuropace | N/A | |
| David Lehman | PulmonxCorp | 63 | |
| Jill Green | Talis Biomedical Corp | N/A | |
| Irene Thomas | Neuropace | 55 | |
| Irina Ridley | Neuropace | 38 | |
| Mehul Joshi | PulmonxCorp | 63 | |
| Sarah Huber | PulmonxCorp | N/A | |
| Jrme Erath | PulmonxCorp | N/A | |
| Emily Faucette | Talis Biomedical Corp | N/A | |
| Teryl Sides | SurModics | 54 | |
| Gordon Weber | SurModics | 61 | |
| Gillian Green | Talis Biomedical Corp | N/A | |
| Rebecca Markovich | Talis Biomedical Corp | 50 | |
| John Manders | SurModics | 43 | |
| Marcee Maroney | PulmonxCorp | 54 | |
Management Performance
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.0723 |
Stryker Leadership Team
Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Silvernail, Independent Director | ||
| Donald Payerle, President Replacement | ||
| Sherilyn McCoy, Independent Director | ||
| Lisa Tatum, Independent Director | ||
| Robert Cohen, CTO Replacement | ||
| Ronda Stryker, Independent Director | ||
| Preston Wells, Vice President - Investor Relations | ||
| Bradford Saar, President Medical | ||
| Spencer Stiles, Group President Orthopaedics and Spine | ||
| Andrew Pierce, Group Neurotechnology | ||
| William Berry, Principal Accounting Officer, Vice President, Corporate Controller | ||
| Allan Golston, Lead Independent Director | ||
| Dragana Bunjevac, Middle Europe | ||
| Stuart Silk, Middle Europe | ||
| Kevin Lobo, Chairman of the Board, President, Chief Executive Officer | ||
| Giovanni Caforio, Independent Director | ||
| Jason Beach, Vice Relations | ||
| Roch Doliveux, Independent Director | ||
| Yin Becker, Vice President - Communications, Public Affairs and Corporate Marketing | ||
| M Fink, Chief Human Resource Officer, Vice President | ||
| Mike Panos, North RD | ||
| Timothy Scannell, Group President of Medsurg and Neurotechnology | ||
| Robert Fletcher, Vice President Chief Legal Officer | ||
| Brian White, President Solutions | ||
| Dylan Crotty, President Instruments | ||
| Brent Ladd, President Endoscopy | ||
| Rajeev Suri, Independent Director | ||
| Alan Douville, Chief VP | ||
| Glenn Boehnlein, Chief Financial Officer, Vice President | ||
| J Pierce, Group President MedSurg and Neurotechnology | ||
| Viju Menon, Group President - Global Quality and Business Operations | ||
| Mary Brainerd, Independent Director | ||
| Srikant Datar, Independent Director | ||
| Maurice BenMayor, President Pacific |
Stryker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.0723 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 138.82 B | ||||
| Shares Outstanding | 380.95 M | ||||
| Shares Owned By Insiders | 5.38 % | ||||
| Shares Owned By Institutions | 79.21 % | ||||
| Number Of Shares Shorted | 4.26 M | ||||
| Price To Earning | 63.07 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Stryker using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Stryker Stock please use our How to buy in Stryker Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Stryker Stock analysis
When running Stryker's price analysis, check to measure Stryker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stryker is operating at the current time. Most of Stryker's value examination focuses on studying past and present price action to predict the probability of Stryker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stryker's price. Additionally, you may evaluate how the addition of Stryker to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Stryker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stryker. If investors know Stryker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stryker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.331 | Dividend Share 3.1 | Earnings Share 8.76 | Revenue Per Share 55.173 | Quarterly Revenue Growth 0.097 |
The market value of Stryker is measured differently than its book value, which is the value of Stryker that is recorded on the company's balance sheet. Investors also form their own opinion of Stryker's value that differs from its market value or its book value, called intrinsic value, which is Stryker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stryker's market value can be influenced by many factors that don't directly affect Stryker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.